SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS, UTILITY ESTIMATES, RESOURCE UTILISATION, AND COSTS IN CHRONIC IDIOPATHIC URTICARIA
Author(s)
Woods MS1, Zimovetz E1, Beard S1, Balp MM21RTI Health Solutions, Manchester, United Kingdom, 2Novartis Pharma AG, Basel, Switzerland
Presentation Documents
OBJECTIVES: To systematically identify economic evaluations of treatments recommended for chronic idiopathic urticaria (CIU) and studies reporting health-state utility weights and/or estimates of resource use and costs. METHODS: Systematic searches of MEDLINE, MEDLINE-In-Process, EconLit, EMBASE, the Cochrane Library, and conference abstracts were conducted from 1 January 2000 to 20 December 2011. Inclusion criteria considered studies reporting utility weights, resource use, costs, and/or economic evaluations of treatments in CIU patients older than 12 years. RESULTS: From 266 retrieved records, 3 studies were included: 1 economic evaluation of levocetirizine and 2 cost studies. The economic evaluation was a pooled analysis of two clinical trials comparing levocetirizine with placebo and incorporating productivity losses defined as absenteeism and/or presenteeism. One cost study reported total annual per-patient direct costs of $1,762; the other study reported a cost range between $1,290 and $2,419, depending on disease severity. Cost components included prescriptions, visits, hospitalisations, and laboratory costs. Annual per-patient indirect costs, defined as disease-related loss of earnings, were between $213 and $484, depending on severity. Although no utility studies in CIU were found, one study demonstrated that CIU severely impairs health-related quality of life at the same level as skin conditions, such as psoriasis and atopic dermatitis, on certain dimensions. CONCLUSIONS: This review identified limited evidence on costs, only one economic evaluation, and no utility data for CIU. Lacking comparative data, it is impossible to conclude what the most cost-effective treatment in CIU might be. Due to discrepancies between the cost studies, it is difficult to conclude which cost component contributed the most; however, one study reported that productivity loss was a major component. This review highlighted the substantial cost burden and a humanistic burden, comparable to other skin disorders, of CIU. Further research in this area is needed.
Conference/Value in Health Info
2012-11, ISPOR Europe 2012, Berlin, Germany
Value in Health, Vol. 15, No. 7 (November 2012)
Code
PRS18
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Respiratory-Related Disorders, Sensory System Disorders